Dec 11, 2023 / 09:30PM GMT
Operator
Thank you for standing by, and welcome to Affimed's clinical data update on Acimtamig AFM13 and AFM24 conference call. (Operator Instructions) Please be advised, today's call is being recorded. I will now turn the call over to your host, Mr. Alex Fudukidis, Director, Investor Relations. Please go ahead.
Alex Fudukidis - Affimed N.V. - Head of IR & Director of IR
Thank you, Valerie.
Good day, everyone, and welcome to Affimed's investor event during the 65th annual American Society of Hematology Annual Meeting and Exposition in San Diego. As a reminder, today's webcast is being recorded and the recording will be available through our website later today.
Before we begin, I'd like to remind everyone that we issued two press releases earlier today, one about our investigator-sponsored combination trial of Acimtamig AFM13 with cord blood-derived natural killer cells data, which was presented earlier today at the ASH conference and a press release on the progress we're making with AFM24 our solid tumor clinical assets.
Before propel --
Affimed NV Conference Call Transcript
Dec 12, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers